Chip Technology Poised to Replace Centrifuges for Superior Blood Plasma Isolation

ExoArc, an innovative device, revolutionizes blood plasma isolation by efficiently removing over 99.9% of blood cells and platelets in a single step, providing high-purity plasma for biomarker analysis and nanoparticle isolation. This technology offers a faster and more precise alternative to traditional centrifugation methods, enabling rapid clinical diagnosis of diseases such as cancer and improving personalized medicine for chronic conditions like diabetes.

Can a Chip Replace the Centrifuge for Blood Plasma Isolation?

The ExoArc device has emerged as a potential game-changer in blood plasma isolation, promising high-quality plasma with exceptional purity. Unlike traditional centrifuges, which rely on spinning blood samples to separate plasma, ExoArc utilizes a microfluidic chip to achieve a more precise and efficient separation process.

How Does ExoArc Achieve Such High Purity?

ExoArc's microfluidic chip leverages unique flow dynamics within tiny channels to separate biological materials based on size. By precisely controlling the flow rates and channel dimensions, the chip effectively removes over 99.9% of blood cells and platelets in a single step. This high level of purity ensures minimal contamination from degraded cellular material, which can lead to inaccurate diagnostic tests.

Clinical Validation: Accurate Cancer Diagnosis

In collaboration with clinicians from the National Cancer Center Singapore (NCCS) and other medical institutions, ExoArc's performance was clinically validated. The device successfully diagnosed non-small cell lung cancer with a sensitivity of 90% by analyzing the microRNA profile of blood plasma. This demonstrates ExoArc's potential for early and accurate cancer detection.

Beyond Cancer: Applications in Diabetes Research

ExoArc's versatility extends beyond cancer diagnosis. The team also demonstrated its utility in studying microRNA molecules from blood plasma samples of individuals with type 2 diabetes mellitus. By identifying 293 different microRNA molecules, the research suggests ExoArc's potential for isolating and identifying disease-related biomarkers in a wide range of conditions.

Benefits for Patients and Clinicians

ExoArc offers several advantages over conventional centrifuges. Its automated and rapid isolation process significantly reduces waiting time for test results, alleviating patient anxiety. Additionally, the high-quality plasma obtained through ExoArc enables more accurate diagnostic tests, leading to improved patient care.

Scaling Up for Clinical Implementation

ExoArc's modular design allows for scaling up by incorporating multiple channels. This feature enables simultaneous isolation of blood plasma from multiple samples, increasing throughput and reducing processing time. Automation of the process further streamlines the diagnostic workflow and potentially reduces overall costs.

Broader Applications: Beyond Blood Plasma

The platform technology underlying ExoArc has the potential to isolate bacteria or viruses from blood or other biofluids by adjusting the size cutoff. This opens up possibilities for rapid pathogen detection and improved diagnostics in infectious disease management.

Funding and Innovation

ExoArc's development is supported by grants from the NTUitive Gap Fund. This funding initiative fosters innovation and entrepreneurship at NTU, transforming research into practical solutions that address societal challenges.

Conclusion

ExoArc represents a significant advancement in blood plasma isolation, offering high purity, rapid processing, and potential applications in a wide range of clinical settings. Its ability to replace centrifuges in the future could revolutionize the way blood samples are processed, leading to improved diagnostic accuracy and patient outcomes.